Your browser doesn't support javascript.
loading
Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
Xie, Jialing; Shen, Xia; Shi, Qin; Yi, Hongmei; Ouyang, Binshen; Zhang, Zhihan; Gu, Yijin; Dong, Lei.
Afiliação
  • Xie J; Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shen X; Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shi Q; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yi H; Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ouyang B; Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhang Z; Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Gu Y; Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Dong L; Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hematol Oncol ; 40(5): 885-893, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36053490
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Fator 88 de Diferenciação Mieloide Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Hematol Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Fator 88 de Diferenciação Mieloide Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Hematol Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China